• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

    30.19 +0.29 (+0.97%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Stoke Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 Next >
    Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics to Present at Upcoming Investor Conferences in August
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021
    Upgrades Janney Montgomery Scott upgraded the previous rating for Centerspace (NYSE:CSR) from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $0.95,... 
    Via Benzinga
    The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
    Via Benzinga
    Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2021
    Upgrades Barrington Research upgraded the previous rating for ViacomCBS Inc (NASDAQ:VIAC) from Market Perform to Outperform. For the first quarter, ViacomCBS had an EPS of... 
    Via Benzinga
    Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.